May 16, 2022 -- Danaher has joined the Bespoke Gene Therapy Consortium (BGTC), which generates gene therapy resources aimed at rare disorders.
Besides Danaher's life science companies such as Pall, Aldevron, and Cytiva, other consortium members include the U.S. Food and Drug Administration, the National Institutes of Health, 12 pharmaceutical and biotech companies, and nine nonprofits. The Foundation for the National Institutes of Health manages the consortium as part of the Accelerating Medicines Partnership program.
The BGTC was formed in October 2021 in response to shortcomings in the current drug development model that makes it difficult for companies to recover the costs required to develop gene therapies to treat rare and ultra-rare diseases, Danaher said.
Copyright © 2022 scienceboard.net